Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes

Diabetes Care

Volumn 35, Issue 1, 2012, Pages 173-174

  Il'yasova, Dora ^a   Spasojevic, Ivan ^a   Base, Karel ^a   Zhang, Haoyue ^b   Wang, Frances ^a   Young, Sarah P ^b   Millington, David S ^b   D'Agostino, Ralph B ^c   Wagenknecht, Lynne E ^c  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY; URINE LEVEL; CASE CONTROL STUDY; CLINICAL TRIAL; GLUCOSE INTOLERANCE; MIDDLE AGED; MULTICENTER STUDY; RISK REDUCTION; URINE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; F2-ISOPROSTANES; FEMALE; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR;

EID: 84859044327     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1502     Document Type: Article

References (10)

1. Basu S. F2-isoprostanes in human health and diseases: from molecularmechanisms to clinical implications. Antioxid Redox Signal 2008;10:1405-1434
2. Keaney JF Jr, Larson MG, Vasan RS, et al.; Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23: 434-439 (Pubitemid 36337219)
3. Meigs JB, Larson MG, Fox CS, Keaney JF Jr, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham-Offspring Study. Diabetes Care 2007; 30:2529-2535 (Pubitemid 47547788)
4. Il'yasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res 2005;13:1638-1644
5. Jackson RA, Hamling JB, Blix PM, Nabarro JD. Relationship among peripheral glucose uptake, oxygen consumption, and glucose turnover in postabsorptive man. J Clin Endocrinol Metab 1984;59:857-860 (Pubitemid 14020684)
6. Wagenknecht LE, Mayer EJ, Rewers M, et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 1995;5: 464-472
7. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group [Internet], 1985. Geneva, World Health Organization, (Tech. Rep. Ser., no. 727). Available from http://whqlibdoc.who.int/ trs/WHO-TRS-727.pdf. Accessed 21 January 2011
8. Il'yasova D, Wang F, D'Agostino RB Jr, Hanley A, Wagenknecht LE. Prospective association between fasting NEFA and type 2 diabetes: impact of post-load glucose. Diabetologia 2010;53:866-874
9. Il'yasova D, Spasojevic I, Wang F, et al. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev 2010;19:1506-1510
10. Tolun AA, Zhang H, Il'yasova D, Sztáray J, Young SP, Millington DS. Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Biochem 2010;402:191-193